{"gene":"GABBR2","run_date":"2026-04-28T17:46:04","timeline":{"discoveries":[{"year":1998,"finding":"GABBR2 (GABA(B)R2) heterodimerizes with GABA(B)R1 to form a functional GABA(B) receptor; neither subunit alone activates GIRK-type potassium channels, but co-expression of both confers robust channel stimulation. The two proteins co-localize in transfected cells and co-immunoprecipitate, consistent with heterodimer formation.","method":"Co-immunoprecipitation, heterologous expression in cells, electrophysiological recording of GIRK channel activity, co-localization by immunofluorescence","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — foundational reconstitution in heterologous cells with functional readout, co-IP, co-localization; highly cited and independently replicated","pmids":["9872315"],"is_preprint":false},{"year":1999,"finding":"Human GABBR2 can couple negatively to adenylyl cyclase in response to GABA, baclofen, and 3-aminopropyl(methyl)phosphinic acid when expressed without GABBR1 in CHO cells, and this effect is blocked by the GABA(B) antagonist 2-hydroxysaclofen. The gene is located on chromosome 9q22.1.","method":"Heterologous expression in CHO cells lacking GABBR1, adenylyl cyclase activity assay, pharmacological antagonism","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro functional assay with pharmacological validation, single lab","pmids":["10328880"],"is_preprint":false},{"year":2000,"finding":"Heteromeric assembly of GABA(B)R1 and GABA(B)R2 is required for functional coupling to endogenous Ca2+ channels in sympathetic neurons; knockdown of GABBR1 via antisense abolished baclofen-mediated inhibition of Ca2+ currents through a pertussis toxin-sensitive (Gi/o) mechanism, and voltage-dependent inhibition was restored by co-expressing both subunits.","method":"Nuclear microinjection of cDNA constructs and antisense in superior cervical ganglion neurons, patch-clamp recording, pertussis toxin treatment","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 — direct neuronal electrophysiology with rescue and loss-of-function, pertussis toxin mechanistic dissection","pmids":["10751439"],"is_preprint":false},{"year":2017,"finding":"De novo GABBR2 variants associated with Rett-like syndrome reduce receptor function, whereas variants linked to epileptic encephalopathy produce a more profound reduction in receptor activity and are more responsive to agonist rescue; variant position in GABBR2 determines phenotypic severity.","method":"Whole-exome sequencing, heterologous cell culture functional assays, Xenopus tropicalis in vivo model, agonist rescue experiments","journal":"Annals of neurology","confidence":"Medium","confidence_rationale":"Tier 2 — cell culture and in vivo functional characterization with multiple variants, single lab","pmids":["28856709"],"is_preprint":false},{"year":2020,"finding":"GABBR2 downregulation in the periaqueductal gray of chronic migraine rats leads to increased glutamate-associated central sensitization; baclofen (GABABR agonist) and PKA inhibitor H89 reduced hyperalgesia and VGLUT2/glutamate/CGRP expression, while CGP35348 (antagonist) and 8-Bromo-cAMP exacerbated it, placing GABBR2 upstream of the PKA/SynCAM1 pathway.","method":"Rat chronic migraine model, intraventricular injection of pharmacological agents, Western blot, qPCR, ELISA, immunofluorescence","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis with multiple pathway readouts in a defined animal model, single lab","pmids":["32931071"],"is_preprint":false},{"year":2020,"finding":"MicroRNA-330 directly targets the 3'UTR of GABBR2 mRNA to suppress its expression in the spinal dorsal horn; miR-330 mimic injection induced abdominal mechanical allodynia in mice, and miR-330 inhibition rescued GABBR2 expression and alleviated pancreatic cancer pain hypersensitivity.","method":"MicroRNA mimic/inhibitor microinjection in vivo, luciferase reporter 3'UTR assay in vitro, Western blot, behavioral pain assays","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase 3'UTR validation plus in vivo rescue, single lab","pmids":["32621101"],"is_preprint":false},{"year":2021,"finding":"GABBR2 promotes post-ischemic angiogenesis by supporting glycolysis in endothelial cells; GABBR2 knockdown in HUVECs impaired proliferation, migration, and tube formation under hypoxia and reduced expression of glycolytic enzymes HKII, PFKFB3, and PKM1, while GABBR2 adenoviral overexpression in mice improved ischemic hindlimb blood flow recovery.","method":"Lentiviral knockdown in HUVECs, in vitro angiogenesis assays, hindlimb ischemia mouse model, XF analyzer (metabolic flux), Western blot, flow cytometry","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo KD/OE with defined metabolic and cellular phenotype, single lab","pmids":["34422926"],"is_preprint":false},{"year":2023,"finding":"GABBR2 is a downstream transcriptional target of the androgen receptor (AR); AR binds the GABBR2 promoter (demonstrated by chromatin immunoprecipitation), and GABBR2 expression promotes cisplatin resistance in bladder cancer cells. GABBR2 knockdown or GABA(B) receptor antagonist CGP46381 enhanced cisplatin cytotoxicity in AR-positive cells.","method":"Chromatin immunoprecipitation (AR binding to GABBR2 promoter), siRNA knockdown, pharmacological antagonism, cell viability assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP provides direct promoter-binding evidence; functional KD with drug response readout, single lab","pmids":["37762034"],"is_preprint":false},{"year":2023,"finding":"HSV-1 latency-associated transcript-encoded miRNAs miR-H3 and miR-H4 directly target the 3'UTR of GABBR2 to repress its expression; luciferase reporter assays confirmed miR-H3 and miR-H4 binding to the GABBR2 3'UTR, and overexpression of these miRNAs in HEK293T cells reduced GABBR2 mRNA levels.","method":"Luciferase 3'UTR reporter assay in HEK293T cells, real-time PCR, transfection of LAT constructs","journal":"Journal of neurovirology","confidence":"Medium","confidence_rationale":"Tier 2 — luciferase 3'UTR validation plus mRNA quantification, single lab","pmids":["37668872"],"is_preprint":false},{"year":2025,"finding":"Epileptic encephalopathy-associated GABBR2 variants (p.A567T, p.S695I, p.I705N) display constitutive gain-of-function activity (50–100% of maximal GABA-induced wild-type activity) in heterologous cells; knock-in mice (Gabbr2I704N/+) show abnormal δ-band EEG synchronization, increased constitutive pre- and postsynaptic GBR activity, reduced agonist responsiveness, and proteomic downregulation of GB1, GB2, and G protein signaling components as an adaptive response. Positive allosteric modulator treatment normalized network activity in these mice.","method":"Luciferase reporter assay in heterologous cells, CRISPR knock-in mouse model, in vitro and in vivo electrophysiology (EEG, brain slices), quantitative proteomics, pharmacological rescue with positive allosteric modulator","journal":"Brain","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods (functional assay, knock-in model, electrophysiology, proteomics, pharmacological rescue) in a single rigorous study","pmids":["40994051"],"is_preprint":false},{"year":2025,"finding":"TAp73α directly binds HDAC2 to disassemble the HDAC2/REST repressor complex, thereby derepressing GABBR2 transcription in melanoma cells; TAp73α-induced GABBR2 upregulation promotes EMT marker expression, cancer cell invasiveness and proliferation.","method":"Multi-omics (transcriptomics, proteomics, cistromics), protein-protein interaction modeling (3D), loss-of-function and gain-of-function experiments in cancer cells","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — multi-omics with mechanistic PPI and functional cellular readouts, single lab","pmids":["40505831"],"is_preprint":false},{"year":2025,"finding":"Conditional knockout of Gabbr2 using a CRISPR-generated floxed allele crossed with ubiquitous Cre mice recapitulates the germline GABBR2 knockout phenotype (epileptiform activity, hyperlocomotion, hyperalgesia, impaired memory, premature death, increased neuronal death, and altered neuronal architecture in cortex, hippocampus, and cerebellum), confirming that GABBR2 loss of function is sufficient to cause these neurological deficits.","method":"CRISPR loxP insertion, Cre-mediated conditional knockout, behavioral testing, histology, immunohistochemistry","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with multiple orthogonal phenotypic readouts across brain regions, recapitulating germline KO","pmids":["41397015"],"is_preprint":false},{"year":2026,"finding":"De novo missense GABBR2 variants associated with neurodevelopmental disorders (ASD, intellectual disability, ADHD) produce distinct functional alterations: (i) increased constitutive activity with decreased GABA efficacy, (ii) reduced GABA potency, or (iii) reduced surface expression with decreased GABA efficacy, as characterized in vitro.","method":"In vitro functional characterization in heterologous cells (luciferase reporter assay), surface expression assay","journal":"NPJ genomic medicine","confidence":"Medium","confidence_rationale":"Tier 1-2 — in vitro functional assays with multiple variants, single lab","pmids":["41803176"],"is_preprint":false},{"year":2026,"finding":"GABBR2 activation by carbamazepine (CBZ) suppresses the adenylyl cyclase/cAMP/PKA signaling pathway in hypothalamic GnRH neurons, triggering apoptosis and reducing GnRH secretion; GABBR2 knockdown in GT1-7 cells attenuated CBZ-induced AC/cAMP/PKA inhibition, rescued apoptosis, and partially restored GnRH secretion.","method":"In vivo rat exposure model, GT1-7 cell GABBR2 knockdown, Western blot, ELISA, cAMP/PKA pathway assays","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — KD rescue in defined cell line with pathway readout, corroborated by in vivo data, single lab","pmids":["41571204"],"is_preprint":false}],"current_model":"GABBR2 encodes the GB2 subunit of the GABA(B) receptor, which obligately heterodimerizes with GB1 (GABBR1) via its transmembrane and coiled-coil domains to form a functional G protein-coupled receptor that activates GIRK potassium channels and inhibits Ca2+ channels and adenylyl cyclase through pertussis toxin-sensitive Gi/o proteins; disease-associated GABBR2 variants cause either gain-of-function constitutive activity (leading to adaptive receptor downregulation and epileptic encephalopathy) or loss-of-function (associated with Rett-like phenotypes), while the receptor is additionally regulated transcriptionally by AR and epigenetically by HDAC2/REST, and post-transcriptionally by miRNAs including miR-330, miR-H3, and miR-H4."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing obligate heterodimerization: demonstration that GABBR2 must partner with GABBR1 to form a functional GABA(B) receptor that activates GIRK channels resolved how the newly cloned subunit contributes to receptor signaling.","evidence":"Co-immunoprecipitation, co-localization, and GIRK channel electrophysiology in heterologous cells","pmids":["9872315"],"confidence":"High","gaps":["Stoichiometry of the heterodimer not determined","Contribution of individual subunit domains to G protein coupling unknown","Native neuronal reconstitution not yet performed"]},{"year":1999,"claim":"Revealing GABBR2 can independently couple to adenylyl cyclase inhibition suggested the subunit possesses intrinsic signaling capacity beyond heterodimerization, though this capacity is pharmacologically consistent with GABA(B) receptor function.","evidence":"Heterologous expression in CHO cells lacking GABBR1 with adenylyl cyclase assay and antagonist block","pmids":["10328880"],"confidence":"Medium","gaps":["Relevance of homomeric GABBR2 signaling in native neurons not confirmed","Whether this activity occurs at physiological expression levels unknown"]},{"year":2000,"claim":"Demonstrating that the GABBR1/GABBR2 heteromer is required for Ca²⁺ channel inhibition via Gi/o proteins in native neurons established the receptor's physiological effector coupling and pertussis toxin sensitivity.","evidence":"Antisense knockdown of GABBR1 and rescue by co-expression of both subunits in sympathetic neurons, with patch-clamp recording and pertussis toxin treatment","pmids":["10751439"],"confidence":"High","gaps":["Whether GB2 directly contacts Gi/o or acts through GB1 not resolved","Structural basis of heterodimer-dependent G protein activation unknown"]},{"year":2017,"claim":"Linking de novo GABBR2 variants to Rett-like syndrome and epileptic encephalopathy with graded loss-of-function severity established GABBR2 as a disease gene and showed that variant position determines phenotype.","evidence":"Whole-exome sequencing, heterologous cell functional assays, Xenopus tropicalis in vivo model, agonist rescue","pmids":["28856709"],"confidence":"Medium","gaps":["Mechanism by which specific variant positions cause graded severity not structurally resolved","Long-term agonist rescue efficacy in mammals not tested"]},{"year":2020,"claim":"Identifying miR-330 and the PKA/SynCAM1 pathway as regulators of GABBR2 expression and downstream signaling in pain models expanded understanding of post-transcriptional control and effector pathways beyond classical neuronal signaling.","evidence":"miR-330 mimic/inhibitor injection with luciferase 3'UTR assay (pain model); pharmacological epistasis in chronic migraine rat model","pmids":["32621101","32931071"],"confidence":"Medium","gaps":["Direct miR-330 regulation of GABBR2 not confirmed in human neurons","PKA/SynCAM1 pathway linkage based on pharmacological epistasis without direct protein interaction data"]},{"year":2021,"claim":"Discovery that GABBR2 promotes post-ischemic angiogenesis by supporting endothelial glycolysis revealed a non-neuronal function for the receptor.","evidence":"Lentiviral knockdown in HUVECs with metabolic flux analysis, and adenoviral overexpression in mouse hindlimb ischemia model","pmids":["34422926"],"confidence":"Medium","gaps":["Whether the angiogenic role requires GABBR1 heterodimerization not tested","Mechanism linking GABBR2 to glycolytic enzyme expression unknown","Single lab finding"]},{"year":2023,"claim":"Identifying AR-driven transcription and HSV-1 miRNA-mediated repression of GABBR2 defined transcriptional and viral post-transcriptional regulatory inputs controlling receptor abundance in disease contexts.","evidence":"ChIP showing AR binding to GABBR2 promoter with knockdown and antagonist validation in bladder cancer cells; luciferase 3'UTR assays confirming miR-H3/miR-H4 targeting","pmids":["37762034","37668872"],"confidence":"Medium","gaps":["AR regulation of GABBR2 not examined in neurons","Physiological relevance of HSV-1 miRNA-mediated GABBR2 repression during latency in vivo not demonstrated"]},{"year":2025,"claim":"Gain-of-function GABBR2 knock-in mice revealed that constitutive receptor activity triggers adaptive proteomic downregulation of GB1, GB2, and G protein components, explaining the paradoxical loss of agonist responsiveness in epileptic encephalopathy; positive allosteric modulator treatment normalized network activity.","evidence":"CRISPR knock-in mouse, EEG, slice electrophysiology, quantitative proteomics, pharmacological rescue with PAM","pmids":["40994051"],"confidence":"High","gaps":["Molecular mechanism of adaptive receptor downregulation (transcriptional vs. degradative) not resolved","Long-term PAM efficacy and safety not assessed"]},{"year":2025,"claim":"Conditional Gabbr2 knockout recapitulated the germline null phenotype — epilepsy, hyperalgesia, memory impairment, premature death — confirming cell-autonomous GABBR2 requirement and validating the floxed allele as a tool for circuit-specific studies.","evidence":"CRISPR-generated floxed Gabbr2 allele crossed with ubiquitous Cre, behavioral and histological phenotyping","pmids":["41397015"],"confidence":"High","gaps":["Cell-type-specific contributions (excitatory vs. inhibitory neurons) not dissected","Whether phenotypes reflect developmental vs. acute loss not distinguished"]},{"year":2025,"claim":"Demonstrating that TAp73α derepresses GABBR2 by displacing HDAC2/REST from its promoter, promoting EMT and invasiveness in melanoma, established a chromatin-level regulatory mechanism for GABBR2 in cancer.","evidence":"Multi-omics (transcriptomics, proteomics, cistromics), 3D protein interaction modeling, gain/loss-of-function in melanoma cells","pmids":["40505831"],"confidence":"Medium","gaps":["Whether HDAC2/REST regulation of GABBR2 occurs in neurons not tested","Direct TAp73α binding to the GABBR2 promoter not shown by ChIP"]},{"year":2026,"claim":"Functional characterization of NDD-associated GABBR2 variants revealed three distinct molecular mechanisms — constitutive activity, reduced GABA potency, and impaired surface trafficking — broadening the genotype-phenotype framework beyond the gain/loss-of-function dichotomy.","evidence":"Luciferase reporter and surface expression assays in heterologous cells for multiple de novo variants","pmids":["41803176"],"confidence":"Medium","gaps":["Variant effects not validated in neuronal systems","Structural basis for trafficking-deficient variants not determined"]},{"year":null,"claim":"The structural basis for how GABBR2's transmembrane domain couples heterodimer-dependent conformational changes to selective G protein activation, and how gain-of-function mutations produce constitutive activity, remains unresolved at atomic resolution.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of disease-mutant GABBR2 heterodimer in active state","Cell-type-specific conditional knockout studies to map circuit-level functions not performed","Whether non-neuronal GABBR2 functions require GABBR1 is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,2,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,2,9]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,12]}],"pathway":[{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,2,9,11]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2,4,13]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,9,12]}],"complexes":["GABA(B) receptor heterodimer (GB1/GB2)"],"partners":["GABBR1","HDAC2","REST","AR","TAP73"],"other_free_text":[]},"mechanistic_narrative":"GABBR2 encodes the GB2 subunit of the metabotropic GABA(B) receptor, which obligately heterodimerizes with GABBR1 (GB1) to form a functional G protein-coupled receptor that inhibits neuronal excitability through activation of GIRK potassium channels, inhibition of Ca²⁺ channels, and suppression of adenylyl cyclase/cAMP/PKA signaling via pertussis toxin-sensitive Gi/o proteins [PMID:9872315, PMID:10751439, PMID:41571204]. Conditional knockout of Gabbr2 causes epileptiform activity, hyperlocomotion, hyperalgesia, impaired memory, and premature death, confirming its essential role in GABAergic inhibitory neurotransmission [PMID:41397015]. De novo GABBR2 missense variants cause a spectrum of neurodevelopmental disorders: gain-of-function constitutive activity variants produce epileptic encephalopathy with adaptive downregulation of receptor and G protein signaling components, while loss-of-function variants are associated with Rett-like syndrome, ASD, and intellectual disability [PMID:28856709, PMID:40994051, PMID:41803176]. GABBR2 transcription is regulated by androgen receptor promoter binding and by TAp73α-mediated displacement of the HDAC2/REST repressor complex, and its mRNA is post-transcriptionally repressed by miR-330 and HSV-1 latency-associated miR-H3/miR-H4 [PMID:37762034, PMID:40505831, PMID:32621101, PMID:37668872]."},"prefetch_data":{"uniprot":{"accession":"O75899","full_name":"Gamma-aminobutyric acid type B receptor subunit 2","aliases":["G-protein coupled receptor 51","HG20"],"length_aa":941,"mass_kda":105.8,"function":"Component of a heterodimeric G-protein coupled receptor for GABA, formed by GABBR1 and GABBR2 (PubMed:15617512, PubMed:18165688, PubMed:22660477, PubMed:24305054, PubMed:9872316, PubMed:9872744). Within the heterodimeric GABA receptor, only GABBR1 seems to bind agonists, while GABBR2 mediates coupling to G proteins (PubMed:18165688). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase (PubMed:10075644, PubMed:10773016, PubMed:24305054). Signaling inhibits adenylate cyclase, stimulates phospholipase A2, activates potassium channels, inactivates voltage-dependent calcium-channels and modulates inositol phospholipid hydrolysis (PubMed:10075644, PubMed:10773016, PubMed:10906333, PubMed:9872744). Plays a critical role in the fine-tuning of inhibitory synaptic transmission (PubMed:22660477, PubMed:9872744). Pre-synaptic GABA receptor inhibits neurotransmitter release by down-regulating high-voltage activated calcium channels, whereas postsynaptic GABA receptor decreases neuronal excitability by activating a prominent inwardly rectifying potassium (Kir) conductance that underlies the late inhibitory postsynaptic potentials (PubMed:10075644, PubMed:22660477, PubMed:9872316, PubMed:9872744). Not only implicated in synaptic inhibition but also in hippocampal long-term potentiation, slow wave sleep, muscle relaxation and antinociception (Probable)","subcellular_location":"Cell membrane; Postsynaptic cell membrane","url":"https://www.uniprot.org/uniprotkb/O75899/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GABBR2","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GABBR2","total_profiled":1310},"omim":[{"mim_id":"617904","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 59; DEE59","url":"https://www.omim.org/entry/617904"},{"mim_id":"617903","title":"NEURODEVELOPMENTAL DISORDER WITH POOR LANGUAGE AND LOSS OF HAND SKILLS; NDPLHS","url":"https://www.omim.org/entry/617903"},{"mim_id":"611195","title":"JANUS KINASE AND MICROTUBULE-INTERACTING PROTEIN 1; JAKMIP1","url":"https://www.omim.org/entry/611195"},{"mim_id":"610464","title":"G PROTEIN-COUPLED RECEPTOR 156; GPR156","url":"https://www.omim.org/entry/610464"},{"mim_id":"607340","title":"GAMMA-AMINOBUTYRIC ACID B RECEPTOR 2; GABBR2","url":"https://www.omim.org/entry/607340"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":62.4}],"url":"https://www.proteinatlas.org/search/GABBR2"},"hgnc":{"alias_symbol":["HG20","GABABR2","GPRC3B"],"prev_symbol":["GPR51"]},"alphafold":{"accession":"O75899","domains":[{"cath_id":"3.40.50.2300","chopping":"54-177_334-421","consensus_level":"medium","plddt":93.2192,"start":54,"end":421},{"cath_id":"1.20.1070","chopping":"479-677","consensus_level":"high","plddt":87.221,"start":479,"end":677}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75899","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75899-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75899-F1-predicted_aligned_error_v6.png","plddt_mean":77.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GABBR2","jax_strain_url":"https://www.jax.org/strain/search?query=GABBR2"},"sequence":{"accession":"O75899","fasta_url":"https://rest.uniprot.org/uniprotkb/O75899.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75899/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75899"}},"corpus_meta":[{"pmid":"9872315","id":"PMC_9872315","title":"GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9872315","citation_count":854,"is_preprint":false},{"pmid":"12081656","id":"PMC_12081656","title":"Expression and distribution of metabotropic GABA receptor subtypes GABABR1 and GABABR2 during rat neocortical development.","date":"2002","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12081656","citation_count":96,"is_preprint":false},{"pmid":"10328880","id":"PMC_10328880","title":"Molecular identification of the human GABABR2: cell surface expression and coupling to adenylyl cyclase in the absence of GABABR1.","date":"1999","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10328880","citation_count":94,"is_preprint":false},{"pmid":"10751439","id":"PMC_10751439","title":"Heteromeric assembly of GABA(B)R1 and GABA(B)R2 receptor subunits inhibits Ca(2+) current in sympathetic neurons.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10751439","citation_count":90,"is_preprint":false},{"pmid":"28856709","id":"PMC_28856709","title":"GABBR2 mutations determine phenotype in rett syndrome and epileptic encephalopathy.","date":"2017","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28856709","citation_count":69,"is_preprint":false},{"pmid":"14961561","id":"PMC_14961561","title":"Comparative cellular distribution of GABAA and GABAB receptors in the human basal ganglia: immunohistochemical colocalization of the alpha 1 subunit of the GABAA receptor, and the GABABR1 and GABABR2 receptor subunits.","date":"2004","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/14961561","citation_count":69,"is_preprint":false},{"pmid":"11304711","id":"PMC_11304711","title":"Differential expression of GABA(B)R1 and GABA(B)R2 receptor immunoreactivity in neurochemically identified neurons of the rat neostriatum.","date":"2001","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11304711","citation_count":38,"is_preprint":false},{"pmid":"11707323","id":"PMC_11707323","title":"Human GABA(B)R genomic structure: evidence for splice variants in GABA(B)R1 but not GABA(B)R2.","date":"2001","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/11707323","citation_count":38,"is_preprint":false},{"pmid":"19763258","id":"PMC_19763258","title":"Association and interaction analyses of GABBR1 and GABBR2 with nicotine dependence in European- and African-American populations.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19763258","citation_count":34,"is_preprint":false},{"pmid":"14967916","id":"PMC_14967916","title":"Identification of GABABR2 in rat testis and sperm.","date":"2003","source":"The Journal of reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/14967916","citation_count":17,"is_preprint":false},{"pmid":"16794563","id":"PMC_16794563","title":"Regulation by nicotine of Gpr51 and Ntrk2 expression in various rat brain regions.","date":"2006","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16794563","citation_count":16,"is_preprint":false},{"pmid":"28490462","id":"PMC_28490462","title":"Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28490462","citation_count":16,"is_preprint":false},{"pmid":"32931071","id":"PMC_32931071","title":"Deficiency in the function of inhibitory interneurons contributes to glutamate-associated central sensitization through GABABR2-SynCAM1 signaling in chronic migraine rats.","date":"2020","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/32931071","citation_count":15,"is_preprint":false},{"pmid":"21371537","id":"PMC_21371537","title":"The level and distribution of the GABA(B)R2 receptor subunit in the rat's central auditory system.","date":"2011","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21371537","citation_count":15,"is_preprint":false},{"pmid":"16538684","id":"PMC_16538684","title":"GABA(B) receptors in the centromedian/parafascicular thalamic nuclear complex: an ultrastructural analysis of GABA(B)R1 and GABA(B)R2 in the monkey thalamus.","date":"2006","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16538684","citation_count":15,"is_preprint":false},{"pmid":"23189044","id":"PMC_23189044","title":"The level and distribution of the GABA(B)R1 and GABA(B)R2 receptor subunits in the rat's inferior colliculus.","date":"2012","source":"Frontiers in neural circuits","url":"https://pubmed.ncbi.nlm.nih.gov/23189044","citation_count":14,"is_preprint":false},{"pmid":"38036272","id":"PMC_38036272","title":"Paeonol ameliorates hippocampal neuronal damage by inhibiting GRM5/GABBR2/β-arrestin2 and activating the cAMP-PKA signaling pathway in premenstrual irritability rats.","date":"2023","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/38036272","citation_count":12,"is_preprint":false},{"pmid":"34422926","id":"PMC_34422926","title":"Endothelial GABBR2 Regulates Post-ischemic Angiogenesis by Inhibiting the Glycolysis Pathway.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34422926","citation_count":11,"is_preprint":false},{"pmid":"32621101","id":"PMC_32621101","title":"MicroRNA-330 Directs Downregulation of the GABABR2 in the Pathogenesis of Pancreatic Cancer Pain.","date":"2020","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/32621101","citation_count":11,"is_preprint":false},{"pmid":"37762034","id":"PMC_37762034","title":"GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37762034","citation_count":10,"is_preprint":false},{"pmid":"36059697","id":"PMC_36059697","title":"miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36059697","citation_count":10,"is_preprint":false},{"pmid":"11716827","id":"PMC_11716827","title":"Subpopulations of neurons in rat substantia nigra display GABA(B)R2 receptor immunoreactivity.","date":"2001","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/11716827","citation_count":9,"is_preprint":false},{"pmid":"38908492","id":"PMC_38908492","title":"Paeonol and glycyrrhizic acid in combination ameliorate the recurrent nitroglycerin-induced migraine-like phenotype in rats by regulating the GABBR2/TRPM8/PRKACA/TRPV1 pathway.","date":"2024","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38908492","citation_count":7,"is_preprint":false},{"pmid":"27033668","id":"PMC_27033668","title":"A GABBR2 gene variant modifies pathophysiology in Huntington's disease.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27033668","citation_count":7,"is_preprint":false},{"pmid":"35414446","id":"PMC_35414446","title":"Paroxysmal limb dystonias associated with GABBR2 pathogenic variant: A case-based literature review.","date":"2022","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/35414446","citation_count":5,"is_preprint":false},{"pmid":"34689406","id":"PMC_34689406","title":"Lactiplantibacillus plantarum HG20 attenuates II type collagen-induced rheumatoid arthritis in rats via anti-inflammatory and inhibition of apoptosis.","date":"2021","source":"Journal of applied microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34689406","citation_count":4,"is_preprint":false},{"pmid":"37668872","id":"PMC_37668872","title":"HSV-1 latency-associated transcript miR-H3 and miR-H4 target STXBP1 and GABBR2 genes.","date":"2023","source":"Journal of neurovirology","url":"https://pubmed.ncbi.nlm.nih.gov/37668872","citation_count":3,"is_preprint":false},{"pmid":"40505831","id":"PMC_40505831","title":"TAp73α drives cancer metastasis via PPI-mediated derepression of the neuronal HDAC2/REST-GABBR2 axis.","date":"2025","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/40505831","citation_count":2,"is_preprint":false},{"pmid":"39724481","id":"PMC_39724481","title":"Increased GABBR2 Expression on Cell Membranes Causes Increased Ca2 + Inward Flow, Associated with Cognitive Impairment in Early Alzheimer's Disease.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39724481","citation_count":2,"is_preprint":false},{"pmid":"40994051","id":"PMC_40994051","title":"Normalization of network activity in an epilepsy model with a constitutively active GABBR2 variant.","date":"2025","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40994051","citation_count":1,"is_preprint":false},{"pmid":"40927314","id":"PMC_40927314","title":"Identification of GABBR2 as a diagnostic marker and its association with Aβ in Alzheimer's disease.","date":"2025","source":"Biochemistry and biophysics reports","url":"https://pubmed.ncbi.nlm.nih.gov/40927314","citation_count":1,"is_preprint":false},{"pmid":"35737203","id":"PMC_35737203","title":"Delayed Expression of Both GABABR1 and GABABR2 Subunits in Murine Hippocampal Dentate Gyrus After a Single Systemic Injection of Trimethyltin.","date":"2022","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/35737203","citation_count":1,"is_preprint":false},{"pmid":"38562171","id":"PMC_38562171","title":"Corrigendum: miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38562171","citation_count":1,"is_preprint":false},{"pmid":"41803176","id":"PMC_41803176","title":"Functional signatures of de novo GABBR1 and GABBR2 variants associated with neurodevelopmental disorders.","date":"2026","source":"NPJ genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41803176","citation_count":0,"is_preprint":false},{"pmid":"41397015","id":"PMC_41397015","title":"Development of a floxed Gabbr2 gene allows for widespread conditional disruption of GABBR2 and recapitulates the phenotype of germline Gabbr2 knockout mice.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/41397015","citation_count":0,"is_preprint":false},{"pmid":"41571204","id":"PMC_41571204","title":"Carbamazepine disrupts the hypothalamic-pituitary-testicular axis and induces hormonal imbalances and sperm damage through activating GABBR2 to inhibit AC/cAMP/PKA pathway.","date":"2026","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/41571204","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.12.669930","title":"Altered molecular signaling pathways in the hippocampus of rhesus monkeys following chronic alcohol use","date":"2025-08-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.12.669930","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.23.634473","title":"Development of a floxed <i>Gabbr2</i> gene allows for widespread conditional disruption of GABBR2 and recapitulates the phenotype of germline Gabbr2 knockout mice","date":"2025-01-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.23.634473","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.22.684016","title":"Proteomic characterization of neuronal extracellular vesicle interactomes in Alzheimer’s disease mouse model through TurboID-based proximity labeling","date":"2025-10-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.22.684016","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.15.24307423","title":"Identifying drug targets for schizophrenia through gene prioritization","date":"2024-05-16","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.15.24307423","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":23685,"output_tokens":3669,"usd":0.063045},"stage2":{"model":"claude-opus-4-6","input_tokens":7064,"output_tokens":2941,"usd":0.163268},"total_usd":0.226313,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"GABBR2 (GABA(B)R2) heterodimerizes with GABA(B)R1 to form a functional GABA(B) receptor; neither subunit alone activates GIRK-type potassium channels, but co-expression of both confers robust channel stimulation. The two proteins co-localize in transfected cells and co-immunoprecipitate, consistent with heterodimer formation.\",\n      \"method\": \"Co-immunoprecipitation, heterologous expression in cells, electrophysiological recording of GIRK channel activity, co-localization by immunofluorescence\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — foundational reconstitution in heterologous cells with functional readout, co-IP, co-localization; highly cited and independently replicated\",\n      \"pmids\": [\"9872315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Human GABBR2 can couple negatively to adenylyl cyclase in response to GABA, baclofen, and 3-aminopropyl(methyl)phosphinic acid when expressed without GABBR1 in CHO cells, and this effect is blocked by the GABA(B) antagonist 2-hydroxysaclofen. The gene is located on chromosome 9q22.1.\",\n      \"method\": \"Heterologous expression in CHO cells lacking GABBR1, adenylyl cyclase activity assay, pharmacological antagonism\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro functional assay with pharmacological validation, single lab\",\n      \"pmids\": [\"10328880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Heteromeric assembly of GABA(B)R1 and GABA(B)R2 is required for functional coupling to endogenous Ca2+ channels in sympathetic neurons; knockdown of GABBR1 via antisense abolished baclofen-mediated inhibition of Ca2+ currents through a pertussis toxin-sensitive (Gi/o) mechanism, and voltage-dependent inhibition was restored by co-expressing both subunits.\",\n      \"method\": \"Nuclear microinjection of cDNA constructs and antisense in superior cervical ganglion neurons, patch-clamp recording, pertussis toxin treatment\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct neuronal electrophysiology with rescue and loss-of-function, pertussis toxin mechanistic dissection\",\n      \"pmids\": [\"10751439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"De novo GABBR2 variants associated with Rett-like syndrome reduce receptor function, whereas variants linked to epileptic encephalopathy produce a more profound reduction in receptor activity and are more responsive to agonist rescue; variant position in GABBR2 determines phenotypic severity.\",\n      \"method\": \"Whole-exome sequencing, heterologous cell culture functional assays, Xenopus tropicalis in vivo model, agonist rescue experiments\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell culture and in vivo functional characterization with multiple variants, single lab\",\n      \"pmids\": [\"28856709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GABBR2 downregulation in the periaqueductal gray of chronic migraine rats leads to increased glutamate-associated central sensitization; baclofen (GABABR agonist) and PKA inhibitor H89 reduced hyperalgesia and VGLUT2/glutamate/CGRP expression, while CGP35348 (antagonist) and 8-Bromo-cAMP exacerbated it, placing GABBR2 upstream of the PKA/SynCAM1 pathway.\",\n      \"method\": \"Rat chronic migraine model, intraventricular injection of pharmacological agents, Western blot, qPCR, ELISA, immunofluorescence\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with multiple pathway readouts in a defined animal model, single lab\",\n      \"pmids\": [\"32931071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MicroRNA-330 directly targets the 3'UTR of GABBR2 mRNA to suppress its expression in the spinal dorsal horn; miR-330 mimic injection induced abdominal mechanical allodynia in mice, and miR-330 inhibition rescued GABBR2 expression and alleviated pancreatic cancer pain hypersensitivity.\",\n      \"method\": \"MicroRNA mimic/inhibitor microinjection in vivo, luciferase reporter 3'UTR assay in vitro, Western blot, behavioral pain assays\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase 3'UTR validation plus in vivo rescue, single lab\",\n      \"pmids\": [\"32621101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GABBR2 promotes post-ischemic angiogenesis by supporting glycolysis in endothelial cells; GABBR2 knockdown in HUVECs impaired proliferation, migration, and tube formation under hypoxia and reduced expression of glycolytic enzymes HKII, PFKFB3, and PKM1, while GABBR2 adenoviral overexpression in mice improved ischemic hindlimb blood flow recovery.\",\n      \"method\": \"Lentiviral knockdown in HUVECs, in vitro angiogenesis assays, hindlimb ischemia mouse model, XF analyzer (metabolic flux), Western blot, flow cytometry\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo KD/OE with defined metabolic and cellular phenotype, single lab\",\n      \"pmids\": [\"34422926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"GABBR2 is a downstream transcriptional target of the androgen receptor (AR); AR binds the GABBR2 promoter (demonstrated by chromatin immunoprecipitation), and GABBR2 expression promotes cisplatin resistance in bladder cancer cells. GABBR2 knockdown or GABA(B) receptor antagonist CGP46381 enhanced cisplatin cytotoxicity in AR-positive cells.\",\n      \"method\": \"Chromatin immunoprecipitation (AR binding to GABBR2 promoter), siRNA knockdown, pharmacological antagonism, cell viability assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP provides direct promoter-binding evidence; functional KD with drug response readout, single lab\",\n      \"pmids\": [\"37762034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HSV-1 latency-associated transcript-encoded miRNAs miR-H3 and miR-H4 directly target the 3'UTR of GABBR2 to repress its expression; luciferase reporter assays confirmed miR-H3 and miR-H4 binding to the GABBR2 3'UTR, and overexpression of these miRNAs in HEK293T cells reduced GABBR2 mRNA levels.\",\n      \"method\": \"Luciferase 3'UTR reporter assay in HEK293T cells, real-time PCR, transfection of LAT constructs\",\n      \"journal\": \"Journal of neurovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — luciferase 3'UTR validation plus mRNA quantification, single lab\",\n      \"pmids\": [\"37668872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Epileptic encephalopathy-associated GABBR2 variants (p.A567T, p.S695I, p.I705N) display constitutive gain-of-function activity (50–100% of maximal GABA-induced wild-type activity) in heterologous cells; knock-in mice (Gabbr2I704N/+) show abnormal δ-band EEG synchronization, increased constitutive pre- and postsynaptic GBR activity, reduced agonist responsiveness, and proteomic downregulation of GB1, GB2, and G protein signaling components as an adaptive response. Positive allosteric modulator treatment normalized network activity in these mice.\",\n      \"method\": \"Luciferase reporter assay in heterologous cells, CRISPR knock-in mouse model, in vitro and in vivo electrophysiology (EEG, brain slices), quantitative proteomics, pharmacological rescue with positive allosteric modulator\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods (functional assay, knock-in model, electrophysiology, proteomics, pharmacological rescue) in a single rigorous study\",\n      \"pmids\": [\"40994051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TAp73α directly binds HDAC2 to disassemble the HDAC2/REST repressor complex, thereby derepressing GABBR2 transcription in melanoma cells; TAp73α-induced GABBR2 upregulation promotes EMT marker expression, cancer cell invasiveness and proliferation.\",\n      \"method\": \"Multi-omics (transcriptomics, proteomics, cistromics), protein-protein interaction modeling (3D), loss-of-function and gain-of-function experiments in cancer cells\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-omics with mechanistic PPI and functional cellular readouts, single lab\",\n      \"pmids\": [\"40505831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Conditional knockout of Gabbr2 using a CRISPR-generated floxed allele crossed with ubiquitous Cre mice recapitulates the germline GABBR2 knockout phenotype (epileptiform activity, hyperlocomotion, hyperalgesia, impaired memory, premature death, increased neuronal death, and altered neuronal architecture in cortex, hippocampus, and cerebellum), confirming that GABBR2 loss of function is sufficient to cause these neurological deficits.\",\n      \"method\": \"CRISPR loxP insertion, Cre-mediated conditional knockout, behavioral testing, histology, immunohistochemistry\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple orthogonal phenotypic readouts across brain regions, recapitulating germline KO\",\n      \"pmids\": [\"41397015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"De novo missense GABBR2 variants associated with neurodevelopmental disorders (ASD, intellectual disability, ADHD) produce distinct functional alterations: (i) increased constitutive activity with decreased GABA efficacy, (ii) reduced GABA potency, or (iii) reduced surface expression with decreased GABA efficacy, as characterized in vitro.\",\n      \"method\": \"In vitro functional characterization in heterologous cells (luciferase reporter assay), surface expression assay\",\n      \"journal\": \"NPJ genomic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro functional assays with multiple variants, single lab\",\n      \"pmids\": [\"41803176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"GABBR2 activation by carbamazepine (CBZ) suppresses the adenylyl cyclase/cAMP/PKA signaling pathway in hypothalamic GnRH neurons, triggering apoptosis and reducing GnRH secretion; GABBR2 knockdown in GT1-7 cells attenuated CBZ-induced AC/cAMP/PKA inhibition, rescued apoptosis, and partially restored GnRH secretion.\",\n      \"method\": \"In vivo rat exposure model, GT1-7 cell GABBR2 knockdown, Western blot, ELISA, cAMP/PKA pathway assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD rescue in defined cell line with pathway readout, corroborated by in vivo data, single lab\",\n      \"pmids\": [\"41571204\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GABBR2 encodes the GB2 subunit of the GABA(B) receptor, which obligately heterodimerizes with GB1 (GABBR1) via its transmembrane and coiled-coil domains to form a functional G protein-coupled receptor that activates GIRK potassium channels and inhibits Ca2+ channels and adenylyl cyclase through pertussis toxin-sensitive Gi/o proteins; disease-associated GABBR2 variants cause either gain-of-function constitutive activity (leading to adaptive receptor downregulation and epileptic encephalopathy) or loss-of-function (associated with Rett-like phenotypes), while the receptor is additionally regulated transcriptionally by AR and epigenetically by HDAC2/REST, and post-transcriptionally by miRNAs including miR-330, miR-H3, and miR-H4.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GABBR2 encodes the GB2 subunit of the metabotropic GABA(B) receptor, which obligately heterodimerizes with GABBR1 (GB1) to form a functional G protein-coupled receptor that inhibits neuronal excitability through activation of GIRK potassium channels, inhibition of Ca²⁺ channels, and suppression of adenylyl cyclase/cAMP/PKA signaling via pertussis toxin-sensitive Gi/o proteins [PMID:9872315, PMID:10751439, PMID:41571204]. Conditional knockout of Gabbr2 causes epileptiform activity, hyperlocomotion, hyperalgesia, impaired memory, and premature death, confirming its essential role in GABAergic inhibitory neurotransmission [PMID:41397015]. De novo GABBR2 missense variants cause a spectrum of neurodevelopmental disorders: gain-of-function constitutive activity variants produce epileptic encephalopathy with adaptive downregulation of receptor and G protein signaling components, while loss-of-function variants are associated with Rett-like syndrome, ASD, and intellectual disability [PMID:28856709, PMID:40994051, PMID:41803176]. GABBR2 transcription is regulated by androgen receptor promoter binding and by TAp73α-mediated displacement of the HDAC2/REST repressor complex, and its mRNA is post-transcriptionally repressed by miR-330 and HSV-1 latency-associated miR-H3/miR-H4 [PMID:37762034, PMID:40505831, PMID:32621101, PMID:37668872].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing obligate heterodimerization: demonstration that GABBR2 must partner with GABBR1 to form a functional GABA(B) receptor that activates GIRK channels resolved how the newly cloned subunit contributes to receptor signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, co-localization, and GIRK channel electrophysiology in heterologous cells\",\n      \"pmids\": [\"9872315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the heterodimer not determined\", \"Contribution of individual subunit domains to G protein coupling unknown\", \"Native neuronal reconstitution not yet performed\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealing GABBR2 can independently couple to adenylyl cyclase inhibition suggested the subunit possesses intrinsic signaling capacity beyond heterodimerization, though this capacity is pharmacologically consistent with GABA(B) receptor function.\",\n      \"evidence\": \"Heterologous expression in CHO cells lacking GABBR1 with adenylyl cyclase assay and antagonist block\",\n      \"pmids\": [\"10328880\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relevance of homomeric GABBR2 signaling in native neurons not confirmed\", \"Whether this activity occurs at physiological expression levels unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstrating that the GABBR1/GABBR2 heteromer is required for Ca²⁺ channel inhibition via Gi/o proteins in native neurons established the receptor's physiological effector coupling and pertussis toxin sensitivity.\",\n      \"evidence\": \"Antisense knockdown of GABBR1 and rescue by co-expression of both subunits in sympathetic neurons, with patch-clamp recording and pertussis toxin treatment\",\n      \"pmids\": [\"10751439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GB2 directly contacts Gi/o or acts through GB1 not resolved\", \"Structural basis of heterodimer-dependent G protein activation unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linking de novo GABBR2 variants to Rett-like syndrome and epileptic encephalopathy with graded loss-of-function severity established GABBR2 as a disease gene and showed that variant position determines phenotype.\",\n      \"evidence\": \"Whole-exome sequencing, heterologous cell functional assays, Xenopus tropicalis in vivo model, agonist rescue\",\n      \"pmids\": [\"28856709\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which specific variant positions cause graded severity not structurally resolved\", \"Long-term agonist rescue efficacy in mammals not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying miR-330 and the PKA/SynCAM1 pathway as regulators of GABBR2 expression and downstream signaling in pain models expanded understanding of post-transcriptional control and effector pathways beyond classical neuronal signaling.\",\n      \"evidence\": \"miR-330 mimic/inhibitor injection with luciferase 3'UTR assay (pain model); pharmacological epistasis in chronic migraine rat model\",\n      \"pmids\": [\"32621101\", \"32931071\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-330 regulation of GABBR2 not confirmed in human neurons\", \"PKA/SynCAM1 pathway linkage based on pharmacological epistasis without direct protein interaction data\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that GABBR2 promotes post-ischemic angiogenesis by supporting endothelial glycolysis revealed a non-neuronal function for the receptor.\",\n      \"evidence\": \"Lentiviral knockdown in HUVECs with metabolic flux analysis, and adenoviral overexpression in mouse hindlimb ischemia model\",\n      \"pmids\": [\"34422926\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the angiogenic role requires GABBR1 heterodimerization not tested\", \"Mechanism linking GABBR2 to glycolytic enzyme expression unknown\", \"Single lab finding\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identifying AR-driven transcription and HSV-1 miRNA-mediated repression of GABBR2 defined transcriptional and viral post-transcriptional regulatory inputs controlling receptor abundance in disease contexts.\",\n      \"evidence\": \"ChIP showing AR binding to GABBR2 promoter with knockdown and antagonist validation in bladder cancer cells; luciferase 3'UTR assays confirming miR-H3/miR-H4 targeting\",\n      \"pmids\": [\"37762034\", \"37668872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AR regulation of GABBR2 not examined in neurons\", \"Physiological relevance of HSV-1 miRNA-mediated GABBR2 repression during latency in vivo not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Gain-of-function GABBR2 knock-in mice revealed that constitutive receptor activity triggers adaptive proteomic downregulation of GB1, GB2, and G protein components, explaining the paradoxical loss of agonist responsiveness in epileptic encephalopathy; positive allosteric modulator treatment normalized network activity.\",\n      \"evidence\": \"CRISPR knock-in mouse, EEG, slice electrophysiology, quantitative proteomics, pharmacological rescue with PAM\",\n      \"pmids\": [\"40994051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of adaptive receptor downregulation (transcriptional vs. degradative) not resolved\", \"Long-term PAM efficacy and safety not assessed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Conditional Gabbr2 knockout recapitulated the germline null phenotype — epilepsy, hyperalgesia, memory impairment, premature death — confirming cell-autonomous GABBR2 requirement and validating the floxed allele as a tool for circuit-specific studies.\",\n      \"evidence\": \"CRISPR-generated floxed Gabbr2 allele crossed with ubiquitous Cre, behavioral and histological phenotyping\",\n      \"pmids\": [\"41397015\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions (excitatory vs. inhibitory neurons) not dissected\", \"Whether phenotypes reflect developmental vs. acute loss not distinguished\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating that TAp73α derepresses GABBR2 by displacing HDAC2/REST from its promoter, promoting EMT and invasiveness in melanoma, established a chromatin-level regulatory mechanism for GABBR2 in cancer.\",\n      \"evidence\": \"Multi-omics (transcriptomics, proteomics, cistromics), 3D protein interaction modeling, gain/loss-of-function in melanoma cells\",\n      \"pmids\": [\"40505831\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HDAC2/REST regulation of GABBR2 occurs in neurons not tested\", \"Direct TAp73α binding to the GABBR2 promoter not shown by ChIP\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Functional characterization of NDD-associated GABBR2 variants revealed three distinct molecular mechanisms — constitutive activity, reduced GABA potency, and impaired surface trafficking — broadening the genotype-phenotype framework beyond the gain/loss-of-function dichotomy.\",\n      \"evidence\": \"Luciferase reporter and surface expression assays in heterologous cells for multiple de novo variants\",\n      \"pmids\": [\"41803176\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Variant effects not validated in neuronal systems\", \"Structural basis for trafficking-deficient variants not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for how GABBR2's transmembrane domain couples heterodimer-dependent conformational changes to selective G protein activation, and how gain-of-function mutations produce constitutive activity, remains unresolved at atomic resolution.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of disease-mutant GABBR2 heterodimer in active state\", \"Cell-type-specific conditional knockout studies to map circuit-level functions not performed\", \"Whether non-neuronal GABBR2 functions require GABBR1 is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 2, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 2, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 2, 9, 11]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2, 4, 13]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 9, 12]}\n    ],\n    \"complexes\": [\n      \"GABA(B) receptor heterodimer (GB1/GB2)\"\n    ],\n    \"partners\": [\n      \"GABBR1\",\n      \"HDAC2\",\n      \"REST\",\n      \"AR\",\n      \"TAp73\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}